Exelixis

Valuation Analysis

About the Company

Exelixis en bref

Exelixis (EXEL) is currently trading at 46,08 € with a market capitalization of 11,6 Md €. The trailing P/E ratio stands at 17.56x, with a forward P/E of 13.1x. The 52-week range spans from 29,34 € to 50,03 €; the current price is 7.9% below the yearly high. Year-over-year revenue growth stands at +10.0%. The net profit margin stands at 35.08%.

💰 Dividende

Exelixis currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

15 analystes évaluent Exelixis (EXEL) au consensus : Acheter. L'objectif de cours moyen est de 45,25 €, soit un potentiel de -1.82% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 35,63 € à 55,62 €.

Exelixis : la thèse d'investissement en détail

Exelixis (EXEL) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 10% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 43.6% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 96.44%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Le scénario baissier

Short interest sits at 16.72% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

• The forward P/E of 13.1x is meaningfully below the trailing 17.56x — analysts expect earnings to step up; the next earnings release is the test.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (16.72%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Exelixis?

Compare top-rated brokers — low fees, trusted providers, fully regulated.